

Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019

<https://marketpublishers.com/r/GF2AFA72A552EN.html>

Date: December 2019

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: GF2AFA72A552EN

Abstracts

Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019'; Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

The report 'Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019' outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted

therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Musculoskeletal Disorders, Genetic Disorders, Ophthalmology and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Lung Cancer, Amyotrophic Lateral Sclerosis, Bladder Cancer, Bone Fracture, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Menkes Disease (Kinky Hair Disease), Metastatic Lung Cancer, Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Pervasive Developmental Disorder (PDD), Retinitis Pigmentosa (Retinitis), Sarcomas, Tauopathies and Unspecified.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycogen Synthase Kinase 3 Beta

(Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or

EC 2.7.11.26 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Actuate Therapeutics Inc

Alzamend Neuro Inc

AMO Pharma Ltd

Angelini Group

Ankar Pharma SL

Avenzoar Pharmaceuticals Inc

CerebraMed

Collaborative Medicinal Development LLC

InnoBioscience LLC

MAIA Biotechnology Inc

Novosteo Inc

Park Active Molecules

Zovis Pharmaceuticals

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles

9-ING41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Unspecified Indication - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-AD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lithium salicylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

manzamine A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBT-826 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK3B for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK3B for Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit GSK3B for Bone Fracture - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tideglusib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B

or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Sep 16, 2019: AMO Pharma participates in Workshop on central nervous system involvement in progression and treatment of Myotonic Dystrophy during Myotonic Dystrophy Foundation Annual Conference

Jun 13, 2019: Updates on development of AMO Pharma's AMO-02 presented at International Myotonic Dystrophy Consortium Meeting

May 06, 2019: AMO Pharma presents statistical analysis of results of phase 2 study of AMO-02 in adolescents with autism spectrum disorder

Dec 17, 2018: Actuate Therapeutics opens phase 1/2 clinical study of 9-ING-41 in patients with refractory cancers

Oct 30, 2018: AMO Pharma reports positive results from AMO-02 trial

Oct 23, 2018: AMO Therapeutics announces presentation of concordant analysis of results of phase 2 study of AMO-02 in treatment of myotonic dystrophy

Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers

Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy

May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research

Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Actuate Therapeutics Inc, H2 2019
Pipeline by Alzamend Neuro Inc, H2 2019
Pipeline by AMO Pharma Ltd, H2 2019
Pipeline by Angelini Group, H2 2019
Pipeline by Ankar Pharma SL, H2 2019
Pipeline by Avenzoar Pharmaceuticals Inc, H2 2019
Pipeline by CerebraMed, H2 2019
Pipeline by Collaborative Medicinal Development LLC, H2 2019
Pipeline by InnoBioscience LLC, H2 2019
Pipeline by MAIA Biotechnology Inc, H2 2019
Pipeline by Novosteo Inc, H2 2019
Pipeline by Park Active Molecules, H2 2019
Pipeline by Zovis Pharmaceuticals, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Actuate Therapeutics Inc

Alzamend Neuro Inc

AMO Pharma Ltd

Angelini Group

Ankar Pharma SL

Avenzoar Pharmaceuticals Inc

CerebraMed

Collaborative Medicinal Development LLC

InnoBioscience LLC

MAIA Biotechnology Inc

Novosteo Inc

Park Active Molecules

Zovis Pharmaceuticals

I would like to order

Product name: Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/GF2AFA72A552EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF2AFA72A552EN.html>